Ibrutinib
Primary Central Nervous System Lymphoma
Explore 71 assets in Primary Central Nervous System Lymphoma →Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07082868CT.gov A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) | — | Recruiting | — | — | — |
NCT04514393CT.gov Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma | — | Unknown | — | — | — |
NCT04421560CT.gov Pembrolizumab, Ibrutinib and Rituximab in PCNSL | — | Recruiting | — | — | — |
NCT04129710CT.gov A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) | — | Unknown | — | — | — |
NCT04066920CT.gov IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL | — | Unknown | — | — | — |
NCT03964090CT.gov Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | — | Active Not Recruiting | — | — | — |
NCT03770416CT.gov Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma | — | Completed | — | — | — |
NCT03703167CT.gov Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) | — | Completed | — | — | — |
NCT03581942CT.gov Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) | — | Completed | — | — | — |
NCT03328078CT.gov CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | — | Recruiting | — | — | — |
Show 4 more trialsShow fewer
NCT02623010CT.gov Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma | — | Unknown | — | — | — |
NCT02542514CT.gov Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma | — | Completed | — | — | — |
NCT02315326CT.gov Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | — | Completed | — | — | — |
NCT02203526CT.gov Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Central Nervous System Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ibrutinib (this asset) | Memorial Sloan Kettering Cancer Center | P2 | BB · 67 |
| Etoposide | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BBB |
| (+)-Vincristine | Ono Pharmaceutical Co., Ltd. | P4 | BBB |
| Adriamycin | Juan P. Alderuccio, MD | P4 | BB |
| Orelabrutinib | The First Affiliated Hospital with Nanjing Medical University | P3 | BB |
| Idarubicin | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BB |
| Cytarabine | The Lymphoma Academic Research Organisation | P4 | BB |
| Dexasone | Allison Winter | P4 | BB |
| Cyclophosphamide | Juan P. Alderuccio, MD | P4 | BB |
+42 more in the Primary Central Nervous System Lymphoma cohort
Other indications for Ibrutinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoid Leukemia | — | P4 | BBB · 72 |
| Waldenstrom Macroglobulinemia | — | P4 | BB · 70 |
| B-Cell Chronic Lymphocytic Leukemia | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- EtoposideFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyBBB
- (+)-VincristineOno Pharmaceutical Co., Ltd.BBB
- AdriamycinJuan P. Alderuccio, MDBB
- OrelabrutinibThe First Affiliated Hospital with Nanjing Medical UniversityBB
- IdarubicinFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyBB
Citation
Floatz Terminal. Ibrutinib in Primary Central Nervous System Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ibrutinib-primary-central-nervous-system-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →